177 related articles for article (PubMed ID: 31136769)
1. Adoption of Abiraterone and Enzalutamide by Urologists.
Caram MEV; Kaufman SR; Modi PK; Herrel L; Oerline M; Ross R; Skolarus TA; Hollenbeck BK; Shahinian V
Urology; 2019 Sep; 131():176-183. PubMed ID: 31136769
[TBL] [Abstract][Full Text] [Related]
2. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
[TBL] [Abstract][Full Text] [Related]
3. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
4. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
5. Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer.
Demus T; Getzenberg RH; Nieder AM
Urol Pract; 2023 Jan; 10(1):90-97. PubMed ID: 37103443
[TBL] [Abstract][Full Text] [Related]
6. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
[TBL] [Abstract][Full Text] [Related]
7. Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.
Lai LY; Kaufman SR; Oerline MK; Caram MEV; Maganty A; Hollenbeck BK; Shahinian VB
JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603854
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
[TBL] [Abstract][Full Text] [Related]
9. A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide.
Woon DTS; Finelli A; Cheung DC; Martin LJ; Alibhai S; Wallis CJD; Diong C; Saskin R; Kulkarni G; Fleshner N
Urology; 2021 Jul; 153():147-155. PubMed ID: 33592224
[TBL] [Abstract][Full Text] [Related]
10. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
11. Observational study on time on treatment with abiraterone and enzalutamide.
Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
[TBL] [Abstract][Full Text] [Related]
12. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Wang X; Yang H; Hu X; Wang W; Yu X; Wang S; Zhang X; Liu L
J Oncol Pharm Pract; 2021 Apr; 27(3):614-622. PubMed ID: 32529950
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
[TBL] [Abstract][Full Text] [Related]
15. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
16. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
17. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
19. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.
Goudarzi Z; Lotfi F; Najafpour Z; Hafezi A; Zakaria MA; Keshavarz K
BMC Urol; 2024 Feb; 24(1):45. PubMed ID: 38378521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
